Vonoprazan trumps PPI in ridding off H. pylori

Pearl Toh
18 Nov 2021
Vonoprazan trumps PPI in ridding off H. pylori

Vonoprazan-containing triple- or dual-therapy regimens are superior to lansoprazole triple therapy in eradicating Helicobacter pylori (H. pylori), according to the phase III pHalcon-HP study presented at ACG 2021.

“Eradication rates with standard PPI*-based triple therapy for H. pylori infection are falling, primarily due to increasing antimicrobial resistance,” said presenting author Dr William Chey of Michigan Medicine at University of Michigan, Ann Arbor, Michigan, US.

“Nearly one-third of US and European patients are not successfully treated by empiric lansoprazole triple therapy,” he noted.

The investigational potassium-competitive acid blocker vonoprazan has been shown to have a faster, stronger, and more durable suppression of gastric acid secretion than PPIs. Vonoprazan inhibits the gastric H+ K+ -ATPase activity, which modulates the last step of the gastric acid secretion pathway.

In the pivotal, multicentre, phase III pHalcon-HP trial, 1,046 adult patients (mean age ~51 years) with H. pylori infection — as indicated by a positive 13C-urea breath test — were randomized 1:1:1 to treatment with PPI-based triple therapy (comprising lansoprazole, amoxicillin, and clarithromycin), vonoprazan triple therapy (with amoxicillin and clarithromycin), or vonoprazan dual therapy (with amoxicillin) for 14 days. Eligible participants have at least one of the following: dyspepsia, history of peptic ulcer, recent/new diagnosis of nonbleeding peptic ulcer, or long-term use of NSAID at stable dose.

The participants were stratified based on resistance status at baseline. For the primary analysis, participants comprised those without strains resistant to clarithromycin or amoxicillin. Secondary endpoints were assessed in all patients as well as in subgroup with clarithromycin-resistant strains. [ACG 2021, abstract 11]

Four weeks after treatment, eradication rates were significantly higher in both the vonoprazan triple- and dual-therapy arms compared with the lansoprazole arm (84.7 percent and 78.5 percent vs 78.8 percent; p<0.0001 and p=0.0037 for each comparison) — thus meeting the primary endpoint of noninferiority to lansoprazole triple therapy in patients with non-resistant strains.

Not only were vonoprazan-containing regimens noninferior to, they were also superior to lansoprazole triple therapy in a prespecified exploratory analysis on the intention-to-treat population (p=0.0408) and the per-protocol population (p=0.0059) among patients with non-resistant strains.

In the overall patient population, both the vonoprazan triple- and dual-therapy regimens were superior to lansoprazole triple therapy (80.8 percent and 77.2 percent vs 68.5 percent; p=0.0001 and p=0.0063, respectively).

When restricting the analysis to patients with clarithromycin-resistant strains, similar results were also seen, with superiority of both the vonoprazan regimens over lansoprazole triple therapy (65.8 percent and 69.6 percent vs 31.9 percent; p<0.0001 for both comparisons). This finding, according to experts, was particularly relevant given the high prevalence of clarithromycin-resistant H. pylori infections seen in practice.

“All study regimens were generally well tolerated,” Chey reported. The rates of treatment-emergent adverse events (TEAEs) were similar across the three treatment arms, at 34.1 percent, 29.9 percent, and 34.5 percent in the vonoprazan triple-, dual-therapy, and lansoprazole arms, respectively. Discontinuation due to TEAEs occurred in 2.3 percent, 0.9 percent, and 1.2 percent of patients, respectively.  

“Vonoprazan dual therapy provides a potential alternative that requires only one antibiotic [compared with the standard PPI-based triple therapy],” said Chey.

 

*PPI: Proton-pump inhibitor

Editor's Recommendations